Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CCL2 | P13500 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557464 | 1.00 | BRD4 (0.49) | BRD4CCL2MEN1KMT2AOPRM1 | |
| SCHEMBL26017423 | 1.00 | BRD4 (0.49) | BRD4CCL2MEN1KMT2AOPRM1 | |
| Formamide SCHEMBL29185076 | 0.91 | BRD4 (0.42) | BRD4CCL2MEN1KMT2AOPRM1 | |
| SCHEMBL8292971 | 0.85 | GPR3 (0.53) | BRD4CCL2LMNAMAPTKDM4E | |
| SCHEMBL7235289 | 0.85 | EGFR (0.47) | BRD4CCL2MEN1KMT2ALMNA | |
| SCHEMBL29925103 | 0.82 | HDAC4 (0.50) | BRD4CCL2OPRM1OPRK1OPRL1 | |
| SCHEMBL1105797 | 0.82 | HDAC4 (0.50) | BRD4CCL2OPRM1OPRK1OPRL1 | |
| SCHEMBL2470207 | 0.82 | AADAT (0.50) | BRD4CCL2MEN1KMT2ALMNA | |
| Iodide SCHEMBL28367716 | 0.80 | HDAC4 (0.48) | BRD4CCL2OPRM1OPRK1OPRL1 | |
| SCHEMBL17974970 | 0.79 | MEN1 (0.49) | MEN1KMT2ALMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106543148-B | A kind of substitution Oxoindole-benzimidazole salt compound and preparation method thereof | 云南大学 | 2019-04-16 | — | — | CN | claimed |
| CN-104114557-B | 8-substituted 2-amino- [1,2,4] triazolo [1,5-a ] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors | 默克专利股份公司 | 2017-10-24 | — | — | CN | claimed |
| CN-106543148-A | It is a kind of to replace Oxoindole-benzimidazole salt compound and preparation method thereof | 云南大学 | 2017-03-29 | — | — | CN | claimed |
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | claimed |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023236920-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-12-14 | — | — | WO | disclosed |
| CN-113880751-A | Green synthesis method of oxindole compound | 台州学院 | 2022-01-04 | — | — | CN | disclosed |
| CN-106232600-B | Indolin-2-one and 1,3- dihydro-pyrrole simultaneously [3,2-c] pyridin-2-ones derivative | 豪夫迈·罗氏有限公司 | 2019-05-14 | — | — | CN | disclosed |
| CN-106543148-B | A kind of substitution Oxoindole-benzimidazole salt compound and preparation method thereof | 云南大学 | 2019-04-16 | — | — | CN | disclosed |
| CN-108101830-A | A kind of preparation method of 3- substitution Oxoindoles and derivative | 中国科学院成都生物研究所 | 2018-06-01 | — | — | CN | disclosed |
| EP-0557289-B1 | 4-(1,2-BENZISOXAZOLYL)PIPERIDINE ANTIPSYCHOTIC AGENTS | PFIZER (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5276040-A | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents | PFIZER INC. (US) | 1994-01-04 | — | — | US | disclosed |
| US-5274117-A | Heating a racemic oxindole, a halogenated acetonitrile and a catalyst to form the alkylated oxindole | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0557289-A1 | 4-(1,2-BENZISOXAZOLYL)PIPERIDINE ANTIPSYCHOTIC AGENTS. | PFIZER (US) | 1993-09-01 | — | — | EP | disclosed |
| US-5147881-A | 4-(1,2-BENZISOXAZOLYL)PIPERIDINE ANTIPSYCHOTIC AGENTS | PFIZER INC (US) | 1992-09-15 | — | — | US | disclosed |
| WO-1992008718-A1 | 4-(1,2-BENZISOXAZOLYL)PIPERIDINE ANTIPSYCHOTIC AGENTS | PFIZER INC. (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0438796-A2 | Process for the enantioselection synthesis of alkylated oxindoles used as intermediates in the preparation of physostigmine | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-31 | — | — | EP | disclosed |
| US-4808601-A | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, NOD1 | BRD4 4014/4885CCL2 1374/4885MEN1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.